Regeneron Pharmaceuticals, Inc. Revenue 2008–2025
Regeneron Pharmaceuticals, Inc. reported $14.34B of revenue for fiscal 2025. That was 1.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +68.8%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $14.34B | +1.0% |
| FY 2024 | $14.20B | +8.3% |
| FY 2023 | $13.12B | +7.8% |
| FY 2022 | $12.17B | -24.3% |
| FY 2021 | $16.07B | +89.1% |
| FY 2020 | $8.50B | +29.6% |
| FY 2019 | $6.56B | +27.4% |
| FY 2018 | $5.15B | -12.4% |
| FY 2017 | $5.87B | +20.8% |
| FY 2016 | $4.86B | +18.4% |
| FY 2015 | $4.10B | +45.5% |
| FY 2014 | $2.82B | +34.0% |
| FY 2013 | $2.10B | +52.7% |
| FY 2012 | $1.38B | +209.2% |
| FY 2011 | $445.82M | -2.9% |
| FY 2010 | $459.07M | +21.0% |
| FY 2009 | $379.27M | +59.1% |
| FY 2008 | $238.46M | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Regeneron Pharmaceuticals, Inc. reported $14.34B of revenue for fiscal 2025. That was 1.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +68.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s revenue?
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.34B for fiscal year 2025, per its SEC filings.
How has Regeneron Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2008 and 2025, REGN's revenue grew at roughly 27.3% per year (compound annual rate), from $238.46M to $14.34B.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.